Building A Better Drug Portfolio: Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), Amgen, Inc. (AMGN)

Page 1 of 2

When building a drug portfolio, most investors stick to pharmaceutical firms. Since these are generally the largest, most profitable options, it’s easy to see why. However, not including a biotechnology company in the mix is a notable weakness in such an approach. While the biotech industry is filled with small, unprofitable companies, one stands out as a giant and it has a place in every drug portfolio.

Pharmaceutical vs Biotechnology

Drugs are an increasingly important aspect of everyday life. With the aging of the Baby Boomers, drug use is set to increase as a large population of future patients moves into their highest medical use years. Add to this the fact that using drugs to treat an illness, despite the often high cost of the drugs involved, can be cheaper than other options, and the trend toward increased drug use seems certain to continue for years to come.

Merck & Co., Inc. (NYSE:MRK)The next big drug, however, isn’t going to show up out of thin air. That means that companies big and small are going to be looking for it. And there are plenty of ailments to target, as even relatively obscure illnesses can prove profitable niches in the drug space.

There are basically two approaches to finding new drugs. One approach, used by pharmaceutical companies, is to examine chemicals that can be beneficial. The other, used by biotechnology companies, examines naturally occurring biological substances as the basis of the research effort. While both are very similar in nature, requiring large up-front research efforts, clinical testing, and Food and Drug Administration approval, the actual processes involved are vastly different.

The pharmaceutical industry is much more mature than the biotech industry, playing host to some of the largest and most profitable companies around. The biotech industry, meanwhile, is often seen as the Wild West, where companies come and go, often at great cost to investors. However, biotechnology is going to be increasingly important in the future and not having some exposure to the industry would be a major mistake if you are building a drug portfolio.

A Solid Portfolio

Finding a good pharmaceutical company doesn’t take a lot of time. Most of the major players are household names and two, Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE), are members of the Dow 30. A third, more diversified drug company, Johnson & Johnson (NYSE:JNJ), is also a Dow member, though its business lineup includes consumer products and medical devices in addition to drugs.

Both Merck & Co., Inc. (NYSE:MRK) and  Pfizer Inc. (NYSE:PFE) would make great additions to a drug portfolio. Each are large participants with notable industry positions. In fact, Pfizer is the largest drug company in the world. Some of the shared strengths of these giants include massive research teams, effective sales forces, and the ability to expand via both internal efforts and mergers and acquisitions. As discovering new drugs becomes increasingly difficult, that last item has become increasingly important.

Johnson & Johnson, meanwhile, is something of a broader industry play, because of its medical device and consumer products divisions. In fact, it is a relatively late entrant into the drug space. That said, the company has a long history of shifting its business over time with acquisitions. The company’s long-term success is very much tied to the successful execution of such transactions, large and small.

All three of these drug companies face similar threats today. The biggest is the fact that some of their most profitable drugs have already lost patent protection, or will find those protections lost in the near future. While each has a pipeline of new drug candidates, the massive profits of successful drugs can be very hard to replace. Still, any of the three would be a good addition to a drug focused portfolio or to provide drug exposure to a more diversified portfolio.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Dangerous Countries for Tourists to Visit

Reign of Terror: The 10 Most Ruthless Politicians in History

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!